Imagine Pharmaceuticals, Inc.
3 articles with Imagine Pharmaceuticals, Inc.
Imagine Pharma Awarded Contract from National Institute of Diabetes and Digestive and Kidney Diseases's Integrated Islet Distribution Program to Provide Human Islets
Imagine Pharma and Regenerative Medicine, announced today that the Integrated Islet Distribution Program (IIDP) has selected it as an approved Islet Isolation Center (IIC).
In a recent interview with BioSpace, Imagine Pharma CEO Ngoc Thai shared the vast potential posed by a polypeptide called IMG-1 to treat Type 1 diabetes.
Imagine Pharma Unveils Industry-First Generation of Insulin-Producing T1D Islet Cell Population at the American Transplant Congress
Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, will showcase its discovery of Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) during its oral presentation today at the American Transplant Congress being held in Boston.